NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY – Get Rating) insider Jeffrey Kunin sold 291,368 shares of the firm’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $0.16, for a total transaction of $46,618.88. Following the sale, the insider now owns 208,632 shares in the company, valued at $33,381.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
NovaBay Pharmaceuticals Stock Performance
Shares of NBY stock opened at $0.14 on Monday. The firm has a market cap of $7.49 million, a PE ratio of -0.82 and a beta of 3.47. NovaBay Pharmaceuticals, Inc. has a one year low of $0.13 and a one year high of $0.77.
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY – Get Rating) last announced its quarterly earnings data on Thursday, August 11th. The biopharmaceutical company reported ($0.04) EPS for the quarter. The firm had revenue of $3.05 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 67.65%. On average, equities analysts forecast that NovaBay Pharmaceuticals, Inc. will post -0.21 EPS for the current fiscal year.
Hedge Funds Weigh In On NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.
- Get a free copy of the StockNews.com research report on NovaBay Pharmaceuticals (NBY)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.